Document Classification

Section Type: RESULTS

Text: Tesaglitazar at doses > or = 1. 0 mg significantly increased high-density lipoprotein-cholesterol (HDL-C) (15. 0 %, 13. 0 %, 12. 9 % ; p < 0. 001), and reduced non-HDL-C (-13. 2 %, -22. 2 %, -25. 0 % ; p < 0. 0001), very-low-density lipoprotein-cholesterol (VLDL-C) (-36. 9 %, -49. 8 %, -52. 5 % ; p < 0. 0001), and total cholesterol (-6. 8 %, -14. 1 %, -15. 5 %, respectively ; p < 0. 01).